Results 81 to 90 of about 32,506 (196)

Atrial cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 727-729, April 2025.
Wojciech Kosmala, Monika Przewłocka‐Kosmala   +1 more
wiley   +1 more source

Clinical Pharmacology of Eplontersen, the First Approved GalNAc‐Conjugated Antisense Oligonucleotide

The Journal of Clinical Pharmacology, Volume 66, Issue 8, August 2026.
Abstract Eplontersen is a GalNAc‐conjugated antisense oligonucleotide (ASO) approved for the treatment of hereditary transthyretin‐mediated amyloidosis with polyneuropathy (ATTRv‐PN). GalNAc conjugation enables targeted hepatic delivery and improved potency compared with unconjugated ASOs.
Rosie Z. Yu, John K. Diep, Xiang Gao, Cecilia Arfvidsson, Angelica Quartino   +4 more
wiley   +1 more source

Early‐Onset Wild‐Type Transthyretin Amyloidosis Polyneuropathy

Muscle &Nerve, EarlyView.
Chafic Karam, Kaylee Baker, Sami Khella, Brian Drachman, Pranav Chandrashekar, MacLean Nasrallah, Shunsuke Koga, Janice Pieretti   +7 more
wiley   +1 more source

Exploring Genetic Therapies Targeting Amyotrophic Lateral Sclerosis in Animal Models: A Systematic Review and Meta‐Analysis

The Journal of Gene Medicine, Volume 28, Issue 8, August 2026.
Amyotrophic lateral sclerosis (ALS) is a rare neurodegenerative disease for which there is currently no known cure. This systematic review explores the efficacy of genetic therapies used to target ALS in preclinical studies using in vivo rodent models. Outcomes investigated include the total number of motor neurons, rodent survival, and muscle function
Hannah E. Wedgwood, Richard I. Tuxworth, Zubair Ahmed   +2 more
wiley   +1 more source

Systemic ATTR-amyloidosis, a Rare Form of Internal Organ Damage [PDF]

, 2019
The article presents the case report of a rare hereditary form of systemic ATTR-amyloidosis in Russian patient with a discussion of approaches to the diagnosis and treatment of this form, also based on the own experience in the management of such ...
S. V. Moiseev, A. S. Rameeva, S. A. Beregovskaya, P. P. Vinogradov, R. P. Myasnikov, S. A. Kostina, L. V. Kozlovskaya, P. P. Tao, L. A. Strizhakov, V. V. Rameev, E. I. Fomicheva, E. A. Mershina, O. M. Drapkina   +12 more
core   +1 more source

Catheter Ablation for Atrial Fibrillation in Cardiac Amyloidosis: A Systematic Review and Meta‐Analysis

Journal of Arrhythmia, Volume 42, Issue 4, August 2026.
This systematic review and meta‐analysis of 13 observational studies found that catheter ablation was associated with lower odds of all‐cause mortality compared with medical management in cardiac amyloidosis and atrial fibrillation. Freedom from atrial arrhythmia after ablation was approximately 50%, with no significant associations for heart failure ...
Adivitch Sripusanapan, Natee Deepan, Bheem Pongsukvechkul, Suphatcha Kittiwongsopon, Min Choon Tan, Pattara Rattanawong, Dan Sorajja, Win‐Kuang Shen, Ronpichai Chokesuwattanaskul, Narut Prasitlumkum   +9 more
wiley   +1 more source

Natural history and outcome in systemic AA amyloidosis [PDF]

, 2007
BACKGROUND:Deposition of amyloid fibrils derived from circulating acute-phase reactant serum amyloid A protein (SAA) causes systemic AA amyloidosis, a serious complication of many chronic inflammatory disorders.
Goodman, HJB, Lachmann, HJ, Gillmore, JD, Hawkins, PN, Gilbertson, JA, Gallimore, JR, Sabin, CA   +6 more
core  

Guidelines for genetic counselling in ATTR amyloidosis [PDF]

Orphanet Journal of Rare Diseases, 2015
Genetic counselling is “a process of communication that deals with the occurrence, or risk of occurrence, of a (possibly) genetic disorder in the family” (ASHG, 1975; EuroGentest guidelines). It involves an attempt, by appropriately trained persons, to help patients and their families to (1) understand the medical facts of the disease; (2) appreciate ...
openaire   +1 more source

Myocardial Work Does Not Have Additional Diagnostic Value in the Assessment of ATTR Cardiac Amyloidosis

, 2021
BACKGROUND: Reduced LV longitudinal strain (GLS) and increased relative apical sparing (RELAPS) and increased wall thickness have been proposed as features for transthyretin cardiac amyloidosis (ATTR-CA).
Henein, Michael Y., Per Lindqvist, Lindqvist, Per,, Michael Y. Henein, Lindqvist, Per, Henein, Michael Y.,   +5 more
core   +1 more source

A Rare Culprit or an Elusive Culprit in Disguise? Unraveling Wild-Type ATTR Cardiac Amyloidosis in Heart Failure With Reduced Ejection Fraction

Journal of Investigative Medicine High Impact Case Reports
Cardiac amyloidosis (CA) is a rare disorder caused by the deposition of abnormal proteins called amyloid in the myocardium, leading to dysfunction. The 2 most common forms of amyloidosis are AL (light chain) and ATTR (transthyretin).
Jose Loayza Pintado MD, Taiwo Ajani MD, Daniela Hernandez MD, Everardo Cobos MD   +3 more
doaj   +1 more source